Literature DB >> 12675213

CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data.

Kazuhiro Inoue1, Eiji Kumazawa, Hiroshi Kuga, Hiroshi Susaki, Noriko Masubuchi, Tetsuyo Kajimura.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675213     DOI: 10.1007/0-306-47932-X_9

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  6 in total

Review 1.  Polymer-drug conjugates: recent development in clinical oncology.

Authors:  Chun Li; Sidney Wallace
Journal:  Adv Drug Deliv Rev       Date:  2008-02-08       Impact factor: 15.470

2.  DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.

Authors:  Moritz N Wente; Jörg Kleeff; Markus W Büchler; Jantien Wanders; Peter Cheverton; Stephen Langman; Helmut Friess
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

Review 3.  Polysaccharide-Based Controlled Release Systems for Therapeutics Delivery and Tissue Engineering: From Bench to Bedside.

Authors:  Tianxin Miao; Junqing Wang; Yun Zeng; Gang Liu; Xiaoyuan Chen
Journal:  Adv Sci (Weinh)       Date:  2018-01-08       Impact factor: 16.806

Review 4.  Macromolecular therapeutics.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

Review 5.  Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.

Authors:  Kohei Shitara; Eishi Baba; Kazumasa Fujitani; Eiji Oki; Satoshi Fujii; Kensei Yamaguchi
Journal:  Gastric Cancer       Date:  2021-05-16       Impact factor: 7.370

6.  Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.

Authors:  Kazuyoshi Kumagai; Tetsuo Aida; Yoshimi Tsuchiya; Yuki Kishino; Kiyonori Kai; Kazuhiko Mori
Journal:  Cancer Sci       Date:  2020-11-02       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.